---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-013727"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T03:21:44.484271+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne Q4 revenue up 5% to $301.3M; GAAP EPS $0.47 vs $0.38, adjusted EPS $0.55 vs $0.51

## Summary
- Full-year organic revenue grew 5% to $1.1B; GAAP EPS $1.76, adjusted EPS $1.99.
- Diagnostics & Genomics segment organic growth 10% in Q4; full-year 8%.
- ExoDx prostate test revenue surged 68% in Q4; GMP proteins up 58%.
- Acquired Lunaphore (COMET spatial biology platform) – no deal value disclosed.
- Quarterly dividend declared $0.08/share, payable Sept 1, record Aug 18.

## SEC filing metadata
- accession: 0001558370-23-013727
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000155837023013727/0001558370-23-013727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000155837023013727/tmb-20230808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-013727
- JSON: https://secwatch.observer/filing/0001558370-23-013727.json
- Plain text: https://secwatch.observer/filing/0001558370-23-013727.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.